25 October 2012
Smiths Medical, a division of global technology business Smiths Group, announces that its advanced safety connector for injecting epidural medication has received clearance from the U.S. Food and Drug Administration (FDA).
The Portex® CorrectInject™ Safety System, designed to reduce the risk of potentially fatal tube misconnections, is the first safety system of its kind to receive a 510(k) clearance from the FDA. This allows it to be marketed in the US.
Smiths Medical President Srini Seshadri said: “As a global leader in safety medical devices, we are delighted to have developed an innovative solution to a long-standing and serious medication delivery issue. FDA clearance is a crucial component in our plans to roll out CorrectInject™ in major markets.”
Misconnections can occur because epidural, intravenous, enteral and other infusion lines are similar. However, the connectors of the CorrectInject™ system are uniquely tapered and threaded to be incompatible with standard intravenous Luer connectors. Its bright yellow components also clearly indicate a neuraxial (spinal and epidural) delivery route. This further reduces the chances of confusing vein-delivered and neuraxial-delivered medication, an error which can cause death or serious illness.
General media enquiries
Contact our global media and communications team at:

Please note – the press team can only answer enquiries from accredited members of the press.
Related articles
![Davinci Gen V Banner Iamge[39]](/media/whpf0qko/davinci-gen-v-banner-iamge-39.jpg?width=431&height=214&format=webp&quality=100&v=1dbb81c2443a690)
Smiths Interconnect announces significant contract win
Read our company news as Smiths Interconnect announces a significant contract win
Find out more
Smiths Interconnect welcomes new EU-Canada security and defence partnership
Find out more
Smiths Group becomes member of the Manufacturing Technology Centre
Read our latest company news as Smiths Group becomes a member of the Manufacturing Technology Centre
Find out more